Crossmark

ASO Visual Abstract: The Role of Cemiplimab in Treating Locally Advanced Cutaneous SCC—A UK Single-Centre Experience and the Implications for Surgical Management

Crossref DOI link: https://doi.org/10.1245/s10434-026-19486-4

Published Online: 2026-03-19

Published Print: 2026-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sharp, Olivia https://orcid.org/0000-0002-8236-4021
Ruccia, Francesca

Tippu, Zayd

Riva, Francesco

Castagnoli, Francesca

Idaikkadar, Praveena

Pickering, Lisa

Paleri, Vinidh

Furness, Andrew

Smith, Myles J.

Hayes, Andrew J.

Power, Kieran
License Information

Text and Data Mining valid from 2026-03-19

Version of Record valid from 2026-03-19
More Information

Article History

First Online: 19 March 2026

Disclosure

: Andrew Furness: Speaking or advisory; BMS, Eisai, Ipsen, Merck and Pfizer: Support for attending meetings and/or travel; Achilles Therapeutics, Adaptimmune, ESMO, Iovance Biotherapeutics Advisory Boards; Achilles Therapeutics, GSK, Immunocore and Neogene Consulting; Iovance Biotherapeutics, BioNTech. Kieran Power: Presentation for Regeneron UK at the BAPRAS meeting UK, Dec 2024, paid £1000.

Document is current

Any future updates will be listed below